A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Inclusion Criteria

• •Histologically confirmed diagnosis of follicular lymphoma, Grade 1, 2, or 3, or diffuse large cell lymphoma concurrent with or following the diagnosis of follicular lymphoma (WHO/REAL classification).
• •International Working Formulation histological equivalents of Follicular, small cleaved; Follicular, mixed small-cleaved and large-cell; follicular large-cell; or Transformed diffuse large cell lymphoma following or concurrent with a diagnosis of follicular lymphoma.
• •Patients diagnosed with diffuse large cell lymphoma at study enrollment must have a historical or contemporaneous lymph node biopsy that demonstrates a diagnosis of follicular lymphoma.
• •Recurrent lymphoma after at least three qualifying therapy regimens including at least one Rituximab-containing regimen and at least one chemotherapy regimen.
• •The patient must have either not responded or responded with a duration of response of less than 6 months to a Rituximab-containing regimen, Performance status of at least 70% on the Karnofsky Scale and an anticipated survival of at least three months.
• •Bi-dimensionally measurable disease with at least one lesion measuring 4.0 cm2 by CT scan.
• •Absolute neutrophil count \>/= 1500 cells/mm3 and platelet count \>/=100,000/mm3 within 21 days prior to study enrollment.
• •Blood products and/or growth factors should not be taken within 4 weeks prior to blood draw.
• •Adequate renal function (defined as serum creatinine \<1.5 x upper limit of normal) and adequate hepatic function (defined as total bilirubin \<1.5x upper limit of normal and AST \<5x upper limit of normal) within 21 days prior to study enrollment.
• •Human Anti-Murine Antibody (HAMA) negative within 21 days prior to study enrollment.
• •Provision of informed consent as signified by a signed IRB approved consent form prior to any study-specific procedures being implemented.